{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:19:17Z","timestamp":1788985157360,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":1782,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA122930"],"award-info":[{"award-number":["R01CA122930"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35CA197725"],"award-info":[{"award-number":["R35CA197725"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS093903"],"award-info":[{"award-number":["R01NS093903"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s13311-018-0650-3","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T14:20:08Z","timestamp":1532010008000},"page":"1127-1138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["A Dendritic Cell-Targeted Adenoviral Vector Facilitates Adaptive Immune Response Against Human Glioma Antigen (CMV-IE) and Prolongs Survival in a Human Glioma Tumor Model"],"prefix":"10.1016","volume":"15","author":[{"given":"Julius W.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Robert","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech K.","family":"Panek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob S.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dou","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Kanojia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanwir","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Miska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"G\u00f3mez-Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya V.","family":"Ulasov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina V.","family":"Balyasnikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atique U.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek A.","family":"Wainwright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej S.","family":"Lesniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1007\/s13311-018-0650-3_bib1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1586\/14737175.2014.917964","article-title":"Therapeutic cell carriers: a potential road to cure glioma","volume":"14","author":"Young","year":"2014","journal-title":"Expert Rev Neurother"},{"key":"10.1007\/s13311-018-0650-3_bib2","series-title":"Janeway's immunobiology","author":"Murphy","year":"2012"},{"key":"10.1007\/s13311-018-0650-3_bib3","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1146\/annurev.immunol.18.1.767","article-title":"Immunobiology of dendritic cells","volume":"18","author":"Banchereau","year":"2000","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"10.1007\/s13311-018-0650-3_bib4","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.smim.2011.01.003","article-title":"Harnessing dendritic cells in cancer","volume":"23","author":"Apetoh","year":"2011","journal-title":"Semin Immunol"},{"key":"10.1007\/s13311-018-0650-3_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fimmu.2012.00013","article-title":"Targeting dendritic cells in vivo for cancer therapy","volume":"3","author":"Caminschi","year":"2012","journal-title":"Front Immunol"},{"key":"10.1007\/s13311-018-0650-3_bib6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3389\/fimmu.2015.00243","article-title":"Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models","volume":"6","author":"Mac Keon","year":"2015","journal-title":"Front Immunol"},{"issue":"3","key":"10.1007\/s13311-018-0650-3_bib7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s11060-013-1350-9","article-title":"Does the existence of HCMV components predict poor prognosis in glioma?","volume":"116","author":"Ding","year":"2014","journal-title":"Journal of Neuro-Oncology"},{"issue":"11","key":"10.1007\/s13311-018-0650-3_bib8","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1158\/0008-5472.CAN-12-3846","article-title":"Cytomegalovirus contributes to glioblastoma in the context of tumor suppressor mutations","volume":"73","author":"Price","year":"2013","journal-title":"Cancer Research"},{"key":"10.1007\/s13311-018-0650-3_bib9","first-page":"4","article-title":"Cytomegalovirus as a novel target for immunotherapy of glioblastoma multiforme","author":"Schuessler","year":"2014","journal-title":"Frontiers in Oncology"},{"issue":"1","key":"10.1007\/s13311-018-0650-3_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5493\/wjem.v5.i1.1","article-title":"Cytomegalovirus in human brain tumors: role in pathogenesis and potential treatment options","volume":"5","author":"S\u00f6derberg-Naucl\u00e9r","year":"2015","journal-title":"World Journal of Experimental Medicine"},{"issue":"39","key":"10.1007\/s13311-018-0650-3_bib11","doi-asserted-by":"crossref","first-page":"12405","DOI":"10.1002\/chem.201403942","article-title":"Selective uptake of cylindrical poly(2-oxazoline) brush-antiDEC205 antibody-OVA antigen conjugates into DEC-positive dendritic cells and subsequent T-cell activation","volume":"20","author":"Buhler","year":"2014","journal-title":"Chemistry"},{"issue":"232","key":"10.1007\/s13311-018-0650-3_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008068","article-title":"Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205","volume":"6","author":"Dhodapkar","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1007\/s13311-018-0650-3_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/imm.12467","article-title":"DNA vaccines encoding DEC205-targeted antigens: immunity or tolerance?","author":"Niezold","year":"2015","journal-title":"Immunology"},{"issue":"10","key":"10.1007\/s13311-018-0650-3_bib14","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.4049\/jimmunol.1400986","article-title":"DEC205+ dendritic cell-targeted tolerogenic vaccination promotes immune tolerance in experimental autoimmune arthritis","volume":"194","author":"Spiering","year":"2015","journal-title":"J Immunol"},{"issue":"1","key":"10.1007\/s13311-018-0650-3_bib15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12033-007-0021-5","article-title":"Adenoviral vectors for gene therapy","volume":"36","author":"Douglas","year":"2007","journal-title":"Molecular Biotechnology"},{"issue":"2","key":"10.1007\/s13311-018-0650-3_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055533","article-title":"An adenovirus vector incorporating carbohydrate binding domains utilizes glycans for gene transfer","volume":"8","author":"Kim","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1007\/s13311-018-0650-3_bib17","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1089\/hum.2015.008","article-title":"A genetically modified adenoviral vector with a phage display-derived peptide incorporated into fiber fibritin chimera prolongs survival in experimental glioma","volume":"26","author":"Kim","year":"2015","journal-title":"Hum Gene Ther"},{"key":"10.1007\/s13311-018-0650-3_bib18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/978-1-4939-3271-9_9","article-title":"Viral vector production: adenovirus","volume":"1382","author":"Kim","year":"2016","journal-title":"Methods Mol Biol"},{"issue":"3","key":"10.1007\/s13311-018-0650-3_bib19","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1172\/JCI78280","article-title":"Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling","volume":"125","author":"Quinn","year":"2015","journal-title":"Journal of Clinical Investigation"},{"issue":"12","key":"10.1007\/s13311-018-0650-3_bib20","doi-asserted-by":"crossref","first-page":"10245","DOI":"10.1128\/JVI.73.12.10245-10253.1999","article-title":"Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset","volume":"73","author":"Rea","year":"1999","journal-title":"J Virol"},{"issue":"2","key":"10.1007\/s13311-018-0650-3_bib21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.virol.2012.12.014","article-title":"Characteristics of neutralizing antibodies to adenovirus capsid proteins in human and animal sera","volume":"437","author":"Yu","year":"2013","journal-title":"Virology"},{"issue":"4","key":"10.1007\/s13311-018-0650-3_bib22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2013.228","article-title":"Circumventing antivector immunity: potential use of nonhuman adenoviral vectors","volume":"25","author":"Lopez-Gordo","year":"2014","journal-title":"Hum Gene Ther"},{"issue":"2","key":"10.1007\/s13311-018-0650-3_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004673","article-title":"Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo","volume":"11","author":"Ma","year":"2015","journal-title":"PLoS Pathog"},{"issue":"11","key":"10.1007\/s13311-018-0650-3_bib24","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1517\/17425247.2014.938637","article-title":"The importance of coagulation factors binding to adenovirus: historical perspectives and implications for gene delivery","volume":"11","author":"Lopez-Gordo","year":"2014","journal-title":"Expert Opin Drug Deliv"},{"issue":"9","key":"10.1007\/s13311-018-0650-3_bib25","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1158\/1535-7163.MCT-10-0332","article-title":"Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy","volume":"9","author":"Short","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"1\u20132","key":"10.1007\/s13311-018-0650-3_bib26","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.virol.2013.09.020","article-title":"Retargeting of gene expression using endothelium specific hexon modified adenoviral vector","volume":"447","author":"Kaliberov","year":"2013","journal-title":"Virology"},{"issue":"1","key":"10.1007\/s13311-018-0650-3_bib27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/sj.gt.3302603","article-title":"An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery","volume":"13","author":"Hedley","year":"2006","journal-title":"Gene Ther"},{"issue":"1","key":"10.1007\/s13311-018-0650-3_bib28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0042-6822(68)90121-9","article-title":"The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12","volume":"36","author":"Maizel","year":"1968","journal-title":"Virology"},{"issue":"13","key":"10.1007\/s13311-018-0650-3_bib29","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/jnci\/djt141","article-title":"A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy","volume":"105","author":"Ahmed","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1007\/s13311-018-0650-3_bib30","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrg2141","article-title":"Engineering targeted viral vectors for gene therapy","volume":"8","author":"Waehler","year":"2007","journal-title":"Nat Rev Genet"},{"issue":"5","key":"10.1007\/s13311-018-0650-3_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125851","article-title":"Incorporation of porcine adenovirus 4 fiber protein enhances infectivity of adenovirus vector on dendritic cells: implications for immune-mediated cancer therapy","volume":"10","author":"Wilkinson-Ryan","year":"2015","journal-title":"PLoS One"},{"issue":"9","key":"10.1007\/s13311-018-0650-3_bib32","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/CJI.0b013e3181b56deb","article-title":"Selective transduction of mature DC in human skin and lymph nodes by CD80\/CD86-targeted fiber-modified adenovirus-5\/3","volume":"32","author":"van de Ven","year":"2009","journal-title":"J Immunother"},{"issue":"7","key":"10.1007\/s13311-018-0650-3_bib33","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/CJI.0b013e3181eccbd4","article-title":"Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus","volume":"33","author":"Hangalapura","year":"2010","journal-title":"J Immunother"},{"issue":"8","key":"10.1007\/s13311-018-0650-3_bib34","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.tips.2012.04.005","article-title":"Adenovirus receptors: implications for targeting of viral vectors","volume":"33","author":"Arnberg","year":"2012","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"10.1007\/s13311-018-0650-3_bib35","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/jgm.1008","article-title":"Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma","volume":"9","author":"Zheng","year":"2007","journal-title":"J Gene Med"},{"issue":"5","key":"10.1007\/s13311-018-0650-3_bib36","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/ijc.20295","article-title":"Gene transfer to cervical cancer with fiber-modified adenoviruses","volume":"111","author":"Rein","year":"2004","journal-title":"Int J Cancer"},{"issue":"13","key":"10.1007\/s13311-018-0650-3_bib37","doi-asserted-by":"crossref","first-page":"6390","DOI":"10.1128\/JVI.00514-11","article-title":"Multimerization of adenovirus serotype 3 fiber knob domains is required for efficient binding of virus to desmoglein 2 and subsequent opening of epithelial junctions","volume":"85","author":"Wang","year":"2011","journal-title":"J Virol"},{"key":"10.1007\/s13311-018-0650-3_bib38","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1401607","article-title":"Dendritic cell-based vaccines that utilize myeloid rather than plasmacytoid cells offer a superior survival advantage in malignant glioma","author":"Dey","year":"2015","journal-title":"J Immunol"},{"issue":"4","key":"10.1007\/s13311-018-0650-3_bib39","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1038\/cti.2016.5","article-title":"A multi-laboratory comparison of blood dendritic cell populations","volume":"5","author":"Fromm","year":"2016","journal-title":"Clin Transl Immunology"},{"issue":"13","key":"10.1007\/s13311-018-0650-3_bib40","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1182\/blood-2001-11-0097","article-title":"Characterization of human blood dendritic cell subsets","volume":"100","author":"MacDonald","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1007\/s13311-018-0650-3_bib41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.smim.2011.01.004","article-title":"Targeting human dendritic cell subsets for improved vaccines","volume":"23","author":"Ueno","year":"2011","journal-title":"Semin Immunol"},{"issue":"5904","key":"10.1007\/s13311-018-0650-3_bib42","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1164206","article-title":"Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity","volume":"322","author":"Hildner","year":"2008","journal-title":"Science"},{"issue":"31","key":"10.1007\/s13311-018-0650-3_bib43","doi-asserted-by":"crossref","first-page":"12716","DOI":"10.1073\/pnas.1203468109","article-title":"Cross-dressed CD8alpha+\/CD103+ dendritic cells prime CD8+ T cells following vaccination","volume":"109","author":"Li","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1007\/s13311-018-0650-3_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067453","article-title":"Targeting antigens to dendritic cells in vivo Induces Protective Immunity","volume":"8","author":"Matos","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1007\/s13311-018-0650-3_bib45","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3109\/07357907.2014.958234","article-title":"Dendritic cell-based vaccine for the treatment of malignant glioma: a systematic review","volume":"32","author":"Wang","year":"2014","journal-title":"Cancer Invest"},{"issue":"16","key":"10.1007\/s13311-018-0650-3_bib46","doi-asserted-by":"crossref","first-page":"6200","DOI":"10.1073\/pnas.0308368101","article-title":"Adenovirus-induced maturation of dendritic cells through a PI3 kinase-mediated TNF-alpha induction pathway","volume":"101","author":"Philpott","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1007\/s13311-018-0650-3_bib47","first-page":"3347","article-title":"Human cytomegalovirus infection and expression in human malignant glioma","volume":"62","author":"Cobbs","year":"2002","journal-title":"Cancer Res"},{"key":"10.1007\/s13311-018-0650-3_bib48","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.canlet.2016.10.022","article-title":"Cytomegalovirus as an oncomodulatory agent in the progression of glioma","volume":"384","author":"Joseph","year":"2017","journal-title":"Cancer Lett"},{"issue":"21","key":"10.1007\/s13311-018-0650-3_bib49","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMc1312413","article-title":"Valganciclovir in patients with glioblastoma","volume":"369","author":"Soderberg-Naucler","year":"2013","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1007\/s13311-018-0650-3_bib50","doi-asserted-by":"crossref","first-page":"25989","DOI":"10.18632\/oncotarget.11175","article-title":"CMV70-3P miRNA contributes to the CMV mediated glioma stemness and represents a target for glioma experimental therapy","volume":"8","author":"Ulasov","year":"2017","journal-title":"Oncotarget"},{"issue":"15","key":"10.1007\/s13311-018-0650-3_bib51","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1158\/0008-5472.CAN-14-3307","article-title":"Cytomegalovirus immediate-early proteins promote stemness properties in glioblastoma","volume":"75","author":"Soroceanu","year":"2015","journal-title":"Cancer Res"},{"issue":"2","key":"10.1007\/s13311-018-0650-3_bib52","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/cdd.2015.91","article-title":"Cytomegalovirus infection induces a stem cell phenotype in human primary glioblastoma cells: prognostic significance and biological impact","volume":"23","author":"Fornara","year":"2016","journal-title":"Cell Death Differ"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-018-0650-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-018-0650-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923010371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923010371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-018-0650-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T19:46:56Z","timestamp":1728676016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923010371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1878747923010371"],"URL":"https:\/\/doi.org\/10.1007\/s13311-018-0650-3","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Dendritic Cell-Targeted Adenoviral Vector Facilitates Adaptive Immune Response Against Human Glioma Antigen (CMV-IE) and Prolongs Survival in a Human Glioma Tumor Model","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-018-0650-3","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}